CGONUp +14.0%CG Oncology
Why CG Oncology (CGON) Stock Rose 14.0% Today
CG Oncology (CGON) rose 14.0% after it said its Phase 3 bladder cancer trial PIVOT-006 met its primary endpoint.
Movers
Monday
Latest trading day covered
CG Oncology
Every big move we have covered on CG Oncology, newest first. Each story gives the answer first and links to the filings and releases behind it.
Last covered move
Close that day$84.78
Figures are from the day of the story, not live quotes.
Why it moved that dayNewest first. Moves and closes are for the day each story covers.
CGONUp +14.0%CG Oncology
CG Oncology (CGON) rose 14.0% after it said its Phase 3 bladder cancer trial PIVOT-006 met its primary endpoint.
SMMT CGON HTHT TSN
Summit Therapeutics fell 16.5% after an FDA Complete Response Letter, and CG Oncology rose 14.0% after trial results. H World and Tyson Foods rose.
CG Oncology, Inc. filings with the SEC from the last 180 days, newest first. We wrote about one of them.
Filings come straight from the SEC's EDGAR database and are listed automatically. They are not written or checked by us. Fetched .
All 54 filings, including insider trade reports. Insider reports filed on the same day are grouped into one row.
Insider trade reports (2)
Form 4Insider trade report
Form 4Quarterly report
10-QResults announced (earnings release)
8-KInsider trade reports (2)
Form 4New insider ownership report
Form 3Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Insider trade report
Form 4Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Insider trade report
Form 4Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Large shareholder report (amended)
SCHEDULE 13G/ALarge shareholder report (amended)
SCHEDULE 13G/ANotice of planned insider sale
Form 144Large shareholder report (amended)
SCHEDULE 13G/ANotice of planned insider sale
Form 144Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Quarterly report
10-QResults announced (earnings release)
8-KAlso: company update
Share offering documents
424B5Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Large shareholder report (amended)
SCHEDULE 13G/ANotice of planned insider sale
Form 144Notice of planned insider sale
Form 144Insider trade report
Form 4Notice of planned insider sale
Form 144Insider trade report
Form 4Notice of planned insider sale
Form 144Notice of planned insider sale
Form 144Insider trade report
Form 4Insider trade report
Form 4Notice of planned insider sale
Form 144Insider trade report
Form 4Notice of planned insider sale
Form 144Insider trade report
Form 4Shareholder vote results
8-KInsider trade reports (6)
Form 4Notice of planned insider sale
Form 144Executive or director change
8-KShowing 8 key filings: company reports, results, annual and quarterly reports, proxies and offerings.
Quarterly report
10-QResults announced (earnings release)
8-KQuarterly report
10-QResults announced (earnings release)
8-KAlso: company update
Share offering documents
424B5Shareholder vote results
8-KExecutive or director change
8-KAs registered with the SEC
Other stocks in the same day's coverage
Summit Therapeutics
Summit Therapeutics (SMMT) fell 16.5% after it said the FDA issued a Complete Response Letter on its application for ivonescimab in lung cancer.
Close $11.82
H World
H World (HTHT) rose 8.9% after the hotel group reported third quarter results and raised its 2026 revenue growth forecast to 9% to 10%.
Close $54.88
Tyson Foods
Tyson Foods (TSN) rose 8.7% after it reported fiscal fourth quarter results and forecast fiscal 2027 adjusted operating income of $1.7 billion to $2.15 billion.
Close $63.95
These stories explain past price moves using public sources. They are not investment advice. See our disclaimer.